selectION, Inc. to Present Update on Clinical Progress at the 42ndAnnual J.P. Morgan Healthcare Conference in San Francisco, CA, on January 11, 2024
Best-in-class Kv1.3 blocker has successfully completed a Phase 1b trial in atopic dermatitis patients Pipeline molecule to treat T cell mediated autoimmune diseases – San Diego, CA, USA, and Munich,…
Read More